Baker Brothers Life Sciences LP
CIK 1363364 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 1,948,876 | $440.91 | $859.28M | $221.65M | 2 | 2026-06-18 |
| INCY | Director | 3,098,808 | $115.90 | $359.15M | $390.15M | 15 | 2026-01-05 |
| KYMR | Director | 7,955,916 | $117.64 | $935.93M | $1.03B | 1 | 2025-12-11 |
| PRLD | Director | — | $3.81 | — | $0 | 2 | 2025-06-13 |
| REPL | Director | — | $12.74 | — | $0 | 1 | 2025-03-07 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,759,462 | $1.27 | $4.77M | $0 | 5 | 2024-10-02 |
| VTVT | Director | — | $26.51 | — | $0 | 1 | 2024-06-27 |
| ACAD | Director | 39,452,627 | $20.18 | $796.24M | $900.00M | 4 | 2024-05-31 |
| BCYC | Director | — | $3.80 | — | $0 | 1 | 2024-05-29 |
| TCRX | Director | 104,698 | $0.19 | $20.2K | $128.25M | 3 | 2024-04-23 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 93,418 | $184.71 | $17.26M | -$1.19B | 3 | 2023-11-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 23,291 | $13.96 | $325.1K | $160.87M | 2 | 2023-08-17 |
| KOD | Director | 1,143,396 | $91.94 | $105.12M | $1.08B | 4 | 2022-07-05 |
| DBVT | Director | 1,341,390 | $10.45 | $14.01M | $0 | 1 | 2022-06-13 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-06-10 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 466,878 | $2.84 | $1.33M | $600.00M | 1 | 2021-02-19 |
| KNSA | Director | — | $86.99 | — | $0 | 1 | 2020-05-18 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 166,122 | — | — | -$403.77M | 11 | 2019-04-10 |
| Neurogene Inc. (AQXP) Delisted | Director | — | — | — | $0 | 1 | 2018-05-09 |
| Seagen Inc. (SGEN) Delisted | Director | 44,865,178 | $228.74 | $10.26B | $2.16B | 6 | 2018-05-02 |
| Aceragen, Inc. (IDRA) Delisted | Director | 30,266 | $7.22 | $218.7K | $0 | 8 | 2018-04-04 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 23,372 | $40.17 | $938.9K | -$62.10M | 5 | 2015-07-23 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 144,482 | — | — | $778.06M | 3 | 2015-01-09 |
Recent Filings · Page 10 of 10
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-01-08 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Buy (P) | +3,438,880 | $163.45M | EDGAR |
| 2012-11-23 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,375,800 | $36.91M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.